Showing results (61-70 of 84) with videos related to
Sort By:
Pageof 9
Cancer Diagnosis & Prognosis|July 5, 2023
Prognosis of Patients Receiving Chemotherapy for Metastatic Upper Tract Urothelial Carcinoma Compared With Metastatic Urinary Bladder CancerShogo Adomi, Kazutoshi Fujita, Hiroyuki Kita, et al.Scientific Reports|October 5, 2022
Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancerYujiro Hayashi, Kazutoshi Fujita, Kazuko Sakai, et al.World Journal of Urology|November 4, 2022
Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patientsTakashi Ueda, Kazutoshi Fujita, Mitsuhisa Nishimoto, et al.Cancer Diagnosis & Prognosis|July 4, 2024
Gleason Pattern 5 May Be a Prognostic Factor in Radium-223 TreatmentMitsuhisa Nishimoto, Kazutoshi Fujita, Aritoshi Ri, et al.In Vivo (Athens, Greece)|April 28, 2025
Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab VedotinMamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.International Journal of Urology : Official Journal of the Japanese Urological Association|August 14, 2025
Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate CancerYutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.Current Oncology (Toronto, Ont.)|June 23, 2022
Trop-2 in Upper Tract Urothelial CarcinomaEisuke Tomiyama, Kazutoshi Fujita, Kosuke Nakano, et al.Translational Andrology and Urology|September 15, 2025
Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumabMamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.International Journal of Clinical Oncology|October 1, 2024
Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitorYutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.Cancer Medicine|May 14, 2025
EIF2S1 in Urinary Extracellular Vesicles as a Novel Diagnostic Marker for Bladder CancerEisuke Tomiyama, Kazutoshi Fujita, Kyosuke Matsuzaki, et al.Pageof 9